ADV SCI 润色咨询

Advanced Science

出版年份：暂无数据 年文章数：3863 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：3.2% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2204586, encodeId=948b2204586bd, content=under review两个半月了，有必要催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec646521427, createdName=ms6000001850112323, createdTime=Tue May 14 09:51:07 CST 2024, time=昨天, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学<br>经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学<br>经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2203988, encodeId=2fcf2203988b9, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：医学;肿瘤;生命科学<br>经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri May 10 22:49:21 CST 2024, time=2024-05-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫治疗<br>经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。<br>11.11 Submitted manuscript to AM<br>11.17 With editor<br>11.21 Edited recommend transfer to Advanced Science<br>11.24 Submitted manuscript to AS<br>12.05 With editor<br>12.05 Under Review<br>12.23 Required Reviews Completed<br>12.24 Major Revision<br>02.14 Revised Manuscript Submitted<br>02.19 Under Review<br>03.05 Required Reviews Completed<br>03.07 Reject<br>03.19 Appeal with editor<br>03.27 Supplement Appeal Material<br>04.11 Editor Suggested to Re-Submit<br>04.12 Re-Submitted to AS<br>04.17 With editor<br>04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础<br>经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海)]
    昨天 ms6000001850112323 来自上海

    under review两个半月了，有必要催一下吗

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2204586, encodeId=948b2204586bd, content=under review两个半月了，有必要催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec646521427, createdName=ms6000001850112323, createdTime=Tue May 14 09:51:07 CST 2024, time=昨天, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学<br>经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学<br>经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2203988, encodeId=2fcf2203988b9, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：医学;肿瘤;生命科学<br>经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri May 10 22:49:21 CST 2024, time=2024-05-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫治疗<br>经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。<br>11.11 Submitted manuscript to AM<br>11.17 With editor<br>11.21 Edited recommend transfer to Advanced Science<br>11.24 Submitted manuscript to AS<br>12.05 With editor<br>12.05 Under Review<br>12.23 Required Reviews Completed<br>12.24 Major Revision<br>02.14 Revised Manuscript Submitted<br>02.19 Under Review<br>03.05 Required Reviews Completed<br>03.07 Reject<br>03.19 Appeal with editor<br>03.27 Supplement Appeal Material<br>04.11 Editor Suggested to Re-Submit<br>04.12 Re-Submitted to AS<br>04.17 With editor<br>04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础<br>经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海)]
    2024-04-20 ms1000000197918585 来自江苏省

    偏重的研究方向：医学
    经验分享：Under Review都快三个月了，这正常吗？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2204586, encodeId=948b2204586bd, content=under review两个半月了，有必要催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec646521427, createdName=ms6000001850112323, createdTime=Tue May 14 09:51:07 CST 2024, time=昨天, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学<br>经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学<br>经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2203988, encodeId=2fcf2203988b9, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：医学;肿瘤;生命科学<br>经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri May 10 22:49:21 CST 2024, time=2024-05-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫治疗<br>经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。<br>11.11 Submitted manuscript to AM<br>11.17 With editor<br>11.21 Edited recommend transfer to Advanced Science<br>11.24 Submitted manuscript to AS<br>12.05 With editor<br>12.05 Under Review<br>12.23 Required Reviews Completed<br>12.24 Major Revision<br>02.14 Revised Manuscript Submitted<br>02.19 Under Review<br>03.05 Required Reviews Completed<br>03.07 Reject<br>03.19 Appeal with editor<br>03.27 Supplement Appeal Material<br>04.11 Editor Suggested to Re-Submit<br>04.12 Re-Submitted to AS<br>04.17 With editor<br>04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础<br>经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海)]
    2024-04-20 ms1000000197918585 来自江苏省

    偏重的研究方向：医学
    经验分享：投了三个月，under review了快三个月，不知道还要等多久

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2204586, encodeId=948b2204586bd, content=under review两个半月了，有必要催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec646521427, createdName=ms6000001850112323, createdTime=Tue May 14 09:51:07 CST 2024, time=昨天, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学<br>经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学<br>经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2203988, encodeId=2fcf2203988b9, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：医学;肿瘤;生命科学<br>经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri May 10 22:49:21 CST 2024, time=2024-05-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫治疗<br>经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。<br>11.11 Submitted manuscript to AM<br>11.17 With editor<br>11.21 Edited recommend transfer to Advanced Science<br>11.24 Submitted manuscript to AS<br>12.05 With editor<br>12.05 Under Review<br>12.23 Required Reviews Completed<br>12.24 Major Revision<br>02.14 Revised Manuscript Submitted<br>02.19 Under Review<br>03.05 Required Reviews Completed<br>03.07 Reject<br>03.19 Appeal with editor<br>03.27 Supplement Appeal Material<br>04.11 Editor Suggested to Re-Submit<br>04.12 Re-Submitted to AS<br>04.17 With editor<br>04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础<br>经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海)]
    2024-05-10 12362864m67暂无昵称 来自湖北省

    审稿速度:2.0 | 投稿命中率:5.0
    偏重的研究方向：医学;肿瘤;生命科学
    经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2204586, encodeId=948b2204586bd, content=under review两个半月了，有必要催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec646521427, createdName=ms6000001850112323, createdTime=Tue May 14 09:51:07 CST 2024, time=昨天, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学<br>经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学<br>经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2203988, encodeId=2fcf2203988b9, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：医学;肿瘤;生命科学<br>经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri May 10 22:49:21 CST 2024, time=2024-05-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫治疗<br>经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。<br>11.11 Submitted manuscript to AM<br>11.17 With editor<br>11.21 Edited recommend transfer to Advanced Science<br>11.24 Submitted manuscript to AS<br>12.05 With editor<br>12.05 Under Review<br>12.23 Required Reviews Completed<br>12.24 Major Revision<br>02.14 Revised Manuscript Submitted<br>02.19 Under Review<br>03.05 Required Reviews Completed<br>03.07 Reject<br>03.19 Appeal with editor<br>03.27 Supplement Appeal Material<br>04.11 Editor Suggested to Re-Submit<br>04.12 Re-Submitted to AS<br>04.17 With editor<br>04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础<br>经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海)]
    2023-08-12 124a8810m95(暂无昵称) 来自重庆

    这个期刊和大CDD比起来怎么样啊？

    10

    展开10条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2204586, encodeId=948b2204586bd, content=under review两个半月了，有必要催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec646521427, createdName=ms6000001850112323, createdTime=Tue May 14 09:51:07 CST 2024, time=昨天, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学<br>经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学<br>经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2203988, encodeId=2fcf2203988b9, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：医学;肿瘤;生命科学<br>经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri May 10 22:49:21 CST 2024, time=2024-05-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫治疗<br>经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。<br>11.11 Submitted manuscript to AM<br>11.17 With editor<br>11.21 Edited recommend transfer to Advanced Science<br>11.24 Submitted manuscript to AS<br>12.05 With editor<br>12.05 Under Review<br>12.23 Required Reviews Completed<br>12.24 Major Revision<br>02.14 Revised Manuscript Submitted<br>02.19 Under Review<br>03.05 Required Reviews Completed<br>03.07 Reject<br>03.19 Appeal with editor<br>03.27 Supplement Appeal Material<br>04.11 Editor Suggested to Re-Submit<br>04.12 Re-Submitted to AS<br>04.17 With editor<br>04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础<br>经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海)]
    2024-04-20 leileiliu 来自陕西省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤免疫治疗
    经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。
    11.11 Submitted manuscript to AM
    11.17 With editor
    11.21 Edited recommend transfer to Advanced Science
    11.24 Submitted manuscript to AS
    12.05 With editor
    12.05 Under Review
    12.23 Required Reviews Completed
    12.24 Major Revision
    02.14 Revised Manuscript Submitted
    02.19 Under Review
    03.05 Required Reviews Completed
    03.07 Reject
    03.19 Appeal with editor
    03.27 Supplement Appeal Material
    04.11 Editor Suggested to Re-Submit
    04.12 Re-Submitted to AS
    04.17 With editor
    04.19 Accept without change

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2204586, encodeId=948b2204586bd, content=under review两个半月了，有必要催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec646521427, createdName=ms6000001850112323, createdTime=Tue May 14 09:51:07 CST 2024, time=昨天, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学<br>经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学<br>经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2203988, encodeId=2fcf2203988b9, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：医学;肿瘤;生命科学<br>经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri May 10 22:49:21 CST 2024, time=2024-05-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫治疗<br>经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。<br>11.11 Submitted manuscript to AM<br>11.17 With editor<br>11.21 Edited recommend transfer to Advanced Science<br>11.24 Submitted manuscript to AS<br>12.05 With editor<br>12.05 Under Review<br>12.23 Required Reviews Completed<br>12.24 Major Revision<br>02.14 Revised Manuscript Submitted<br>02.19 Under Review<br>03.05 Required Reviews Completed<br>03.07 Reject<br>03.19 Appeal with editor<br>03.27 Supplement Appeal Material<br>04.11 Editor Suggested to Re-Submit<br>04.12 Re-Submitted to AS<br>04.17 With editor<br>04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础<br>经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海)]
    2022-12-14 ms6000000798925478 来自广东省

    12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞

    11

    展开11条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2204586, encodeId=948b2204586bd, content=under review两个半月了，有必要催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec646521427, createdName=ms6000001850112323, createdTime=Tue May 14 09:51:07 CST 2024, time=昨天, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学<br>经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学<br>经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2203988, encodeId=2fcf2203988b9, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：医学;肿瘤;生命科学<br>经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri May 10 22:49:21 CST 2024, time=2024-05-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫治疗<br>经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。<br>11.11 Submitted manuscript to AM<br>11.17 With editor<br>11.21 Edited recommend transfer to Advanced Science<br>11.24 Submitted manuscript to AS<br>12.05 With editor<br>12.05 Under Review<br>12.23 Required Reviews Completed<br>12.24 Major Revision<br>02.14 Revised Manuscript Submitted<br>02.19 Under Review<br>03.05 Required Reviews Completed<br>03.07 Reject<br>03.19 Appeal with editor<br>03.27 Supplement Appeal Material<br>04.11 Editor Suggested to Re-Submit<br>04.12 Re-Submitted to AS<br>04.17 With editor<br>04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础<br>经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海)]
    2023-10-19 ms10085448 来自江苏省

    大修送回去，要审多久才有消息啊？听说有的要两三个月……

    6

    展开6条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2204586, encodeId=948b2204586bd, content=under review两个半月了，有必要催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec646521427, createdName=ms6000001850112323, createdTime=Tue May 14 09:51:07 CST 2024, time=昨天, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学<br>经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学<br>经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2203988, encodeId=2fcf2203988b9, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：医学;肿瘤;生命科学<br>经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri May 10 22:49:21 CST 2024, time=2024-05-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫治疗<br>经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。<br>11.11 Submitted manuscript to AM<br>11.17 With editor<br>11.21 Edited recommend transfer to Advanced Science<br>11.24 Submitted manuscript to AS<br>12.05 With editor<br>12.05 Under Review<br>12.23 Required Reviews Completed<br>12.24 Major Revision<br>02.14 Revised Manuscript Submitted<br>02.19 Under Review<br>03.05 Required Reviews Completed<br>03.07 Reject<br>03.19 Appeal with editor<br>03.27 Supplement Appeal Material<br>04.11 Editor Suggested to Re-Submit<br>04.12 Re-Submitted to AS<br>04.17 With editor<br>04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础<br>经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海)]
    2023-12-28 ms1000000907051820 来自河南省

    偏重的研究方向：医学;医学基础
    经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪

    10

    展开10条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2204586, encodeId=948b2204586bd, content=under review两个半月了，有必要催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec646521427, createdName=ms6000001850112323, createdTime=Tue May 14 09:51:07 CST 2024, time=昨天, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学<br>经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学<br>经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2203988, encodeId=2fcf2203988b9, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：医学;肿瘤;生命科学<br>经验分享：一审两个审稿人，都给了Top15%，大修两个月时间，需要补很多实验。其中审稿人1一直在批评创新性不够，这种情况返修回去机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Fri May 10 22:49:21 CST 2024, time=2024-05-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫治疗<br>经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。<br>11.11 Submitted manuscript to AM<br>11.17 With editor<br>11.21 Edited recommend transfer to Advanced Science<br>11.24 Submitted manuscript to AS<br>12.05 With editor<br>12.05 Under Review<br>12.23 Required Reviews Completed<br>12.24 Major Revision<br>02.14 Revised Manuscript Submitted<br>02.19 Under Review<br>03.05 Required Reviews Completed<br>03.07 Reject<br>03.19 Appeal with editor<br>03.27 Supplement Appeal Material<br>04.11 Editor Suggested to Re-Submit<br>04.12 Re-Submitted to AS<br>04.17 With editor<br>04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础<br>经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海)]
    2024-04-04 123cda67m26(暂无昵称) 来自上海

    怎么这么慢，with editory已经9天了

    1

    展开1条回复
共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分